SCHEMBL17536725

SCHEMBL17536725

O=c1[nH]c2cccnc2c2[nH]ncc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 6/20 0.59
KDM4E B2RXH2 1/20 0.49
CDK4 P11802 1/20 0.42
CCND1 P24385 1/20 0.42
GABRA1 P14867 2/20 0.41
GABRG2 P18507 2/20 0.41
GABRB3 P28472 2/20 0.41
GABRA5 P31644 2/20 0.41
GABRA3 P34903 2/20 0.41
GABRA2 P47869 2/20 0.41
XDH P47989 1/20 0.41
ADORA3 P0DMS8 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
METAP2 P50579 1/20 0.40
DAO P14920 1/20 0.40
ATAD2 Q6PL18 1/20 0.40
PDE9A O76083 2/20 0.39
AURKA O14965 1/20 0.39
PDE2A O00408 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23495851 0.78 METAP2 (0.55) PARP1KDM4ECDK4CCND1GABRA1
SCHEMBL29615757 0.78 METAP2 (0.55) PARP1KDM4ECDK4CCND1GABRA1
SCHEMBL30273114 0.77 METAP2 (0.62) PARP1KDM4EADORA3METAP2DAO
SCHEMBL14796578 0.77 METAP2 (0.62) PARP1KDM4EADORA3METAP2DAO
SCHEMBL14933613 0.76 PARP1 (0.77) PARP1KDM4ECDK4CCND1GABRA1
SCHEMBL2411557 0.76 AURKA (0.60) PARP1CDK4CCND1GABRA1GABRG2
SCHEMBL12750384 0.75 PARP1 (1.00) PARP1KDM4ECDK4CCND1GABRA1
SCHEMBL15338391 0.71 PARP1 (1.00) PARP1KDM4ECDK4CCND1GABRA1
SCHEMBL30910462 0.71 PARP1 (1.00) PARP1KDM4ECDK4CCND1GABRA1
SCHEMBL17536709 0.71 PARP1 (0.58) PARP1XDHMETAP2DAOPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856257-B2 Pyrazolonaphthyridinone derivatives as MetAP2 inhibitors (methionine aminopeptidase type-2) SANOFI (FR) 2018-01-02 US disclosed
EP-2978764-B1 PYRAZOLONAPHTHYRIDINONE DERIVATIVES AS METAP2 INHIBITORS (METHIONINE AMINOPEPTIDASE TYPE-2) SANOFI SA (FR) 2017-04-19 EP disclosed
US-20160060265-A1 PYRAZOLONAPHTHYRIDINONE DERIVATIVES AS METAP2 INHIBITORS (METHIONINE AMINOPEPTIDASE TYPE-2) SANOFI (FR) 2016-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060265-A1 PYRAZOLONAPHTHYRIDINONE DERIVATIVES AS METAP2 INHIBITORS (METHIONINE AMINOPEPTIDASE TYPE-2) METAP2, METAP1, XPNPEP2 PARP1 2711/4885KDM4E 2975/4885CDK4 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.